Search Results

Search

Ethics Talk: Public, Civic and Spiritual Health During COVID

Submitted by Audiey.Kao@ama… on

In this video and podcast edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Patrick Smith about intersections of public health, civic good and spiritual well-being during this COVID-19 pandemic. 

Click here to read the transcript. 

Patrick Smith, PhD, MA, MDiv is associate research professor of theological ethics and bioethics at the Duke Divinity School, senior fellow at the Kenan Institute for Ethics at Duke University, and core faculty with the Trent Center for Bioethics, Humanities, and History of Medicine at Duke University School of Medicine. 

Video

Recorded on April 23, 2021

Audio

 

Conflict of Interest Disclosure
Interviewee had no conflicts of interest to disclose.

Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.

Header Image image Issue Compassionate Force CME Off
History of Medicine
Sep 2018

Why Does the Shift from “Personalized Medicine” to “Precision Health” and “Wellness Genomics” Matter?

Eric T. Juengst, PhD and Michelle L. McGowan, PhD
Transitions in relabeling personalized medicine as precision medicine, precision health, or wellness genomics reflect shifting the locus of responsibility for health from individuals to clinicians and in shifting focus from genetic risk to genetic enhancement.
AMA J Ethics. 2018;20(9):E881-890. doi: 10.1001/amajethics.2018.881.
Art of Medicine
Sep 2018

The Precision Portrait

Samuel Rodriguez, MD and Nick Love, PhD
This portrait of a child against a backdrop of health data suggests how a patient’s individuality can be obscured when precision medicine is used in decision making and developing target therapies.
AMA J Ethics. 2018;20(9):E891-893. doi: 10.1001/amajethics.2018.891.
image
Podcast
Sep 2018

Ethics Talk: Protecting Patients and Promoting Inclusivity in Precision Health Research

Large precision health initiatives like the National Institutes of Health’s All of Us campaign raise important ethical questions about consent, privacy, and inclusivity. This month on Ethics Talk, we explore with Dr Katie Johansen Taber and Ysabel Duron strategies for protecting participants and ensuring that diverse communities are represented.
Health Law
Dec 2019

What Is Prudent Governance of Human Genome Editing?

Scott J. Schweikart, JD, MBE
The Asilomar Conference of 1975 and the German Ethics Council offer guidance for a path towards prudent regulation in the face of unknown and significant risks.
AMA J Ethics. 2019;21(12):E1042-1048. doi: 10.1001/amajethics.2019.1042.
Health Law
Dec 2019

Is Gene Editing Patentable?

Lisa M. Gehrke, JD, MA
Although advisory groups like the World Health Organization question whether certain forms of gene editing should be permitted, the US Patent Office routinely issues patents protecting this technology.
AMA J Ethics. 2019;21(12):E1049-1055. doi: 10.1001/amajethics.2019.1049.
Medicine and Society
Dec 2019

An Exclusive Interview With CRISPR

Sean C. McConnell, PhD
Clinically and ethically relevant questions are related to patient safety, therapeutic efficacy, equitable access, and global governance over humanity’s genetic legacy.
AMA J Ethics. 2019;21(12):E1079-1088. doi: 10.1001/amajethics.2019.1079.
Medicine and Society
Dec 2019

What Should Clinicians Do to Engage the Public About Gene Editing?

Tom Alsaigh, MD, Laura Nicholson, MD, PhD, and Eric Topol, MD
Clinicians should have a working understanding of gene editing, controversy surrounding its use, and its far-reaching clinical and ethical implications.
AMA J Ethics. 2019;21(12):E1089-1097. doi: 10.1001/amajethics.2019.1089.